Emmanuel Mignot

Publications

• HLA-DQ association and allele competition in Chinese narcolepsy. Han F, Lin L, Li J, Dong SX, An P, Zhao L, Liu NY, Li QY, Yan H, Gao ZC, Faraco J, Strohl KP, Liu X, Miyadera H, Mignot E. Tissue Antigens. 2012; 80 (4): 328-35
• Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, Melberg A, Cornelio F, Urban AE, Pizza F, Poli F, Grubert F, Wieland T, Graf E, Hallmayer J, Strom TM, Mignot E. Hum Mol Genet. 2012; 21 (10): 2205-10
• Common variants in P2RY11 are associated with narcolepsy. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, Axtell RC, Kuipers H, Weiner K, Hamacher A, Kassack MU, Han F, Knudsen S, Li J, Dong X, Winkelmann J, Plazzi G, Nevsimalova S, Hong SC, Honda Y, Honda M, Högl B, Ton TG, Montplaisir J, Bourgin P, Kemlink D, Huang YS, Warby S, Einen M, Eshragh JL, Miyagawa T, Desautels A, Ruppert E, Hesla PE, Poli F, Pizza F, Frauscher B, Jeong JH, Lee SP, Strohl KP, Longstreth WT, Kvale M, Dobrovolna M, Ohayon MM, Nepom GT, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Peppard P, Young T, Jennum P, Steinman L, Tokunaga K, Kwok PY, Risch N, Hallmayer J, Mignot E. Nat Genet. 2011; 43 (1): 66-71
• Genetics of sleep and sleep disorders. Sehgal A, Mignot E. Cell. 2011; 146 (2): 194-207
• Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, Yan H, Gao ZC, Yuan Y, Strohl KP, Mignot E. Ann Neurol. 2011; 70 (3): 410-7
• IGFBP3 colocalizes with and regulates hypocretin (orexin). Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, Salehi A, Hesla PE, Maehlen J, Gaus SE, Yanagisawa M, Sakurai T, Taheri S, Tsuchiya K, Honda Y, Mignot E. PLoS One. 2009; 4 (1): e4254
• Narcolepsy is strongly associated with the T-cell receptor alpha locus. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, Mayer G, Plazzi G, Nevsimalova S, Bourgin P, Hong SC, Hong SS, Honda Y, Honda M, Högl B, Longstreth WT, Montplaisir J, Kemlink D, Einen M, Chen J, Musone SL, Akana M, Miyagawa T, Duan J, Desautels A, Erhardt C, Hesla PE, Poli F, Frauscher B, Jeong JH, Lee SP, Ton TG, Kvale M, Kolesar L, Dobrovolná M, Nepom GT, Salomon D, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Young T, Peppard P, Tokunaga K, Kwok PY, Risch N, Mignot E. Nat Genet. 2009; 41 (6): 708-11
• Cataplexy features in childhood narcolepsy. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Mov Disord. 2008; 23 (6): 858-65
• Kleine-Levin syndrome: a systematic study of 108 patients. Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P, Zeitzer J, Lo B, Faraco JH, Mignot E. Ann Neurol. 2008; 63 (4): 482-93
• Why we sleep: the temporal organization of recovery. Mignot E, PLoS Biol. 2008; 6 (4): e106
• Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Mignot E, Lin L, Finn L, Lopes C, Pluff K, Sundstrom ML, Young T. Brain. 2006; 129 (Pt 6): 1609-23
• Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. Taheri S, Lin L, Austin D, Young T, Mignot E. PLoS Med. 2004; 1 (3): e62
• The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S. Arch Neurol. 2002; 59 (10): 1553-62
• Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, Okun M, Hohjoh H, Miki T, Hsu S, Leffell M, Grumet F, Fernandez-Vina M, Honda M, Risch N. Am J Hum Genet. 2001; 68 (3): 686-99
• A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. Nat Med. 2000; 6 (9): 991-7
• The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. Cell. 1999; 98 (3): 365-76
• Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Sleep. 1999; 22 (1): 77-87
• Pharmacological aspects of human and canine narcolepsy. Nishino S, Mignot E. Prog Neurobiol. 1997; 52 (1): 27-78
• Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Psychopharmacology (Berl). 1993; 113 (1): 76-82
• Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. Mignot E, Nishino S, Sharp LH, Arrigoni J, Siegel JM, Reid MS, Edgar DM, Ciaranello RD, Dement WC. J Neurosci. 1993; 13 (3): 1057-64
• Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin. Pizza F, Moghadam KK, Vandi S, Detto S, Poli F, Mignot E, Ferri R, Plazzi G. J Sleep Res. 2013; 22 (1): 32-40
• CSF levels of hypocretin-1 (orexin-A) peak during early infancy in humans. Aran A, Shors I, Lin L, Mignot E, Schimmel MS. Sleep. 2012; 35 (2): 187-91
• DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status. Weiner Lachmi K, Lin L, Kornum BR, Rico T, Lo B, Aran A, Mignot E. Hum Immunol. 2012; 73 (4): 405-10
• Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Knudsen S, Biering-Sørensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, Mignot E, Jennum PJ. Neurology. 2012; 79 (1): 102-3
• TCRA, P2RY11, and CPT1B/CHKB associations in Chinese narcolepsy. Han F, Lin L, Li J, Aran A, Dong SX, An P, Zhao L, Li QY, Yan H, Wang JS, Gao HY, Li M, Gao ZC, Strohl KP, Mignot E. Sleep Med. 2012; 13 (3): 269-72
• Time-course of cerebrospinal fluid histamine in the wake-consolidated squirrel monkey. Zeitzer JM, Kodama T, Buckmaster CL, Honda Y, Lyons DM, Nishino S, Mignot E. J Sleep Res. 2012; 21 (2): 189-94
• β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study. Vardeny O, Peppard PE, Finn LA, Faraco JH, Mignot E, Hla KM. J Am Soc Hypertens. 2011 Mar-Apr; 5 (2): 114-22
• Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Plazzi G, Pizza F, Palaia V, Franceschini C, Poli F, Moghadam KK, Cortelli P, Nobili L, Bruni O, Dauvilliers Y, Lin L, Edwards MJ, Mignot E, Bhatia KP. Brain. 2011; 134 (Pt 12): 3480-92
• Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. Winkelmann J, Czamara D, Schormair B, Knauf F, Schulte EC, Trenkwalder C, Dauvilliers Y, Polo O, Högl B, Berger K, Fuhs A, Gross N, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Xiong L, Montplaisir J, Rouleau GA, Fietze I, Vávrová J, Kemlink D, Sonka K, Nevsimalova S, Lin SC, Wszolek Z, Vilariño-Güell C, Farrer MJ, Gschliesser V, Frauscher B, Falkenstetter T, Poewe W, Allen RP, Earley CJ, Ondo WG, Le WD, Spieler D, Kaffe M, Zimprich A, Kettunen J, Perola M, Silander K, Cournu-Rebeix I, Francavilla M, Fontenille C, Fontaine B, Vodicka P, Prokisch H, Lichtner P, Peppard P, Faraco J, Mignot E, Gieger C, Illig T, Wichmann HE, Müller-Myhsok B, Meitinger T. PLoS Genet. 2011; 7 (7): e1002171
• Narcolepsy with cataplexy associated with nocturnal compulsive behaviors: a case-control study. Palaia V, Poli F, Pizza F, Antelmi E, Franceschini C, Moghadam KK, Provini F, Pagotto U, Montagna P, Schenck CH, Mignot E, Plazzi G. Sleep. 2011; 34 (10): 1365-71
• Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Kornum BR, Faraco J, Mignot E. Curr Opin Neurobiol. 2011; 21 (6): 897-903
• Post-streptococcal antibodies are associated with metabolic syndrome in a population-based cohort. Aran A, Lin L, Finn LA, Weiner K, Peppard P, Young T, Mignot E. PLoS One. 2011; 6 (9): e25017
• Presentations of primary hypersomnia in Chinese children. Han F, Lin L, Li J, Aran A, Dong SX, An P, Zhao L, Li M, Li QY, Yan H, Wang JS, Gao HY, Li M, Gao ZC, Strohl KP, Mignot E. Sleep. 2011; 34 (5): 627-32
• Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Kawashima M, Lin L, Tanaka S, Jennum P, Knudsen S, Nevsimalova S, Plazzi G, Mignot E. Sleep. 2010; 33 (7): 869-74
• Behavioural and neurophysiological correlates of human cataplexy: a video-polygraphic study. Vetrugno R, D'Angelo R, Moghadam KK, Vandi S, Franceschini C, Mignot E, Montagna P, Plazzi G. Clin Neurophysiol. 2010; 121 (2): 153-62
• Circadian and homeostatic regulation of structural synaptic plasticity in hypocretin neurons. Appelbaum L, Wang G, Yokogawa T, Skariah GM, Smith SJ, Mourrain P, Mignot E. Neuron. 2010; 68 (1): 87-98
• Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Aran A, Einen M, Lin L, Plazzi G, Nishino S, Mignot E. Sleep. 2010; 33 (11): 1457-64
• DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue. Goel N, Banks S, Mignot E, Dinges DF. Neurology. 2010; 75 (17): 1509-19
• Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. J Appl Physiol. 2010; 109 (4): 1053-63
• Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks. Plazzi G, Tonon C, Rubboli G, Poli F, Franceschini C, Pizza F, Bisulli A, Rizzo G, Mignot E, Montagna P, Lodi R. Mov Disord. 2010; 25 (6): 788-90
• Post-H1N1 narcolepsy-cataplexy. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, Kawashima M, Bayard S, Monaca C, Tiberge M, Filipini D, Tripathy A, Nguyen BH, Kotagal S, Mignot E. Sleep. 2010; 33 (11): 1428-30
• Post-streptococcal auto-antibodies inhibit protein disulfide isomerase and are associated with insulin resistance. Aran A, Weiner K, Lin L, Finn LA, Greco MA, Peppard P, Young T, Ofran Y, Mignot E. PLoS One. 2010; 5 (9): e12875
• Sleep well and stay slim: dream or reality? Taheri S, Mignot E. Ann Intern Med. 2010; 153 (7): 475-6
• Sodium oxybate is an effective and safe treatment for narcolepsy. Lammers GJ, Bassetti C, Billiard M, Black J, Broughton R, Dauvilliers Y, Ferini Strambi L, Garcia-Borreguero D, Goswami M, Högl B, Iranzo A, Jennum P, Khatami R, Lecendreux M, Mayer G, Mignot E, Montplaisir J, Nevsimalova S, Peraita-Adrados R, Plazzi G, Scammell T, Silber M, Sonka K, Tafti M, Thorpy M. Sleep Med. 2010; 11 (1): 105-6; author reply 106-8
• Transcriptional regulation of the hypocretin/orexin gene by NR6A1. Tanaka S, Kodama T, Nonaka T, Toyoda H, Arai M, Fukazawa M, Honda Y, Honda M, Mignot E. Biochem Biophys Res Commun. 2010; 403 (2): 178-83
• Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. Honda M, Arai T, Fukazawa M, Honda Y, Tsuchiya K, Salehi A, Akiyama H, Mignot E. Neurology. 2009; 73 (7): 511-7
• Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Poli F, Plazzi G, Di Dalmazi G, Ribichini D, Vicennati V, Pizza F, Mignot E, Montagna P, Pasquali R, Pagotto U. Sleep. 2009; 32 (11): 1491-7
• Characterization of two melanin-concentrating hormone genes in zebrafish reveals evolutionary and physiological links with the mammalian MCH system. Berman JR, Skariah G, Maro GS, Mignot E, Mourrain P. J Comp Neurol. 2009; 517 (5): 695-710
• Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Nishino S, Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, Mignot E. Sleep. 2009; 32 (2): 175-80
• Distribution of neurochemical abnormalities in patients with narcolepsy with cataplexy: An in vivo brain proton MR spectroscopy study. Tonon C, Franceschini C, Testa C, Manners DN, Poli F, Mostacci B, Mignot E, Montagna P, Barbiroli B, Lodi R, Plazzi G. Brain Res Bull. 2009; 80 (3): 147-50
• Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, Zeitzer J, Mignot E. Sleep. 2009; 32 (8): 979-83
• Modafinil and γ-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep. Zeitzer JM, Buckmaster CL, Landolt HP, Lyons DM, Mignot E. Behav Pharmacol. 2009; 20 (7): 643-52
• Resting our cortices by going DOWN to sleep. Mignot E, Huguenard JR. Neuron. 2009; 63 (6): 719-21
• Sleep-wake regulation and hypocretin-melatonin interaction in zebrafish. Appelbaum L, Wang GX, Maro GS, Mori R, Tovin A, Marin W, Yokogawa T, Kawakami K, Smith SJ, Gothilf Y, Mignot E, Mourrain P. Proc Natl Acad Sci U S A. 2009; 106 (51): 21942-7
• T-box 3 is expressed in the adult mouse hypothalamus and medulla. Eriksson KS, Mignot E. Brain Res. 2009: 1302 233-9
• Anomalous hypothalamic responses to humor in cataplexy. Reiss AL, Hoeft F, Tenforde AS, Chen W, Mobbs D, Mignot EJ. PLoS One. 2008; 3 (5): e2225
• CSF hypocretin-1 assessment in sleep and neurological disorders. Bourgin P, Zeitzer JM, Mignot E. Lancet Neurol. 2008; 7 (7): 649-62
• Excessive daytime sleepiness: population and etiology versus nosology. Mignot E, Sleep Med Rev. 2008; 12 (2): 87-94
• Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Mishima K, Fujiki N, Yoshida Y, Sakurai T, Honda M, Mignot E, Nishino S. Sleep. 2008; 31 (8): 1119-26
• Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, Mignot E, Cicognani A, Montagna P. J Neurol. 2008; 255 (10): 1549-54
• Sleep and EEG features in genetic models of Down syndrome. Colas D, Valletta JS, Takimoto-Kimura R, Nishino S, Fujiki N, Mobley WC, Mignot E. Neurobiol Dis. 2008; 30 (1): 1-7
• Sympathetic and cardiovascular activity during cataplexy in narcolepsy. Donadio V, Plazzi G, Vandi S, Franceschini C, Karlsson T, Montagna P, Vetrugno R, Bugiardini E, Mignot E, Liguori R. J Sleep Res. 2008; 17 (4): 458-63
• The hypocretin neurotransmission system in myotonic dystrophy type 1. Ciafaloni E, Mignot E, Sansone V, Hilbert JE, Lin L, Lin X, Liu LC, Pigeon WR, Perlis ML, Thornton CA. Neurology. 2008; 70 (3): 226-30
• The type III neurofilament peripherin is expressed in the tuberomammillary neurons of the mouse. Eriksson KS, Zhang S, Lin L, Larivière RC, Julien JP, Mignot E. BMC Neurosci. 2008: 9 26
• Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, Fujimoto A, Shimada M, Morishita S, Shigeta T, Lin L, Hong SC, Faraco J, Shin YK, Jeong JH, Okazaki Y, Tsuji S, Honda M, Honda Y, Mignot E, Tokunaga K. Nat Genet. 2008; 40 (11): 1324-8
• A circadian sleep disorder reveals a complex clock. Mignot E, Takahashi JS. Cell. 2007; 128 (1): 22-3
• A step forward for restless legs syndrome. Mignot E, Nat Genet. 2007; 39 (8): 938-9
• Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Rubio JP, Bahlo M, Stankovich J, Burfoot RK, Johnson LJ, Huxtable S, Butzkueven H, Lin L, Taylor BV, Speed TP, Kilpatrick TJ, Mignot E, Foote SJ. Immunogenetics. 2007; 59 (3): 177-86
• Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. Yokogawa T, Marin W, Faraco J, Pézeron G, Appelbaum L, Zhang J, Rosa F, Mourrain P, Mignot E. PLoS Biol. 2007; 5 (10): e277
• Comparative expression of p2x receptors and ecto-nucleoside triphosphate diphosphohydrolase 3 in hypocretin and sensory neurons in zebrafish. Appelbaum L, Skariah G, Mourrain P, Mignot E. Brain Res. 2007: 1174 66-75
• Correlates of serum C-reactive protein (CRP)--no association with sleep duration or sleep disordered breathing. Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E. Sleep. 2007; 30 (8): 991-6
• DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hong SC, Lin L, Lo B, Jeong JH, Shin YK, Kim SY, Kweon Y, Zhang J, Einen M, Smith A, Hansen J, Grumet FC, Mignot E. Hum Immunol. 2007; 68 (1): 59-68
• Depression: relationships to sleep paralysis and other sleep disturbances in a community sample. Szklo-Coxe M, Young T, Finn L, Mignot E. J Sleep Res. 2007; 16 (3): 297-312
• English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary. Schenck CH, Bassetti CL, Arnulf I, Mignot E. J Clin Sleep Med. 2007; 3 (3): 301-11
• Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Renier C, Faraco JH, Bourgin P, Motley T, Bonaventure P, Rosa F, Mignot E. Pharmacogenet Genomics. 2007; 17 (4): 237-53
• Increasing length of wakefulness and modulation of hypocretin-1 in the wake-consolidated squirrel monkey. Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E. Am J Physiol Regul Integr Comp Physiol. 2007; 293 (4): R1736-42
• Narcolepsy with cataplexy. Dauvilliers Y, Arnulf I, Mignot E. Lancet. 2007; 369 (9560): 499-511
• Normal cerebrospinal fluid levels of hypocretin-1 (orexin A) in patients with fibromyalgia syndrome. Taiwo OB, Russell IJ, Mignot E, Lin L, Michalek JE, Haynes W, Xiao Y, Zeitzer JM, Larson AA. Sleep Med. 2007; 8 (3): 260-5
• REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Nevsimalova S, Prihodova I, Kemlink D, Lin L, Mignot E. Sleep Med. 2007; 8 (7-8): 784-6
• Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain. Lindberg J, Saetre P, Nishino S, Mignot E, Jazin E. BMC Neurosci. 2007: 8 34
• Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy. Zhang S, Zeitzer JM, Sakurai T, Nishino S, Mignot E. J Physiol. 2007; 581 (Pt 2): 649-63
• The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Zhang S, Lin L, Kaur S, Thankachan S, Blanco-Centurion C, Yanagisawa M, Mignot E, Shiromani PJ. Neuroscience. 2007; 148 (1): 34-43
• A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Hong SC, Lin L, Jeong JH, Shin YK, Han JH, Lee JH, Lee SP, Zhang J, Einen M, Mignot E. Sleep. 2006; 29 (11): 1429-38
• CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? Arnulf I, Lin L, Zhang J, Russell IJ, Ripley B, Einen M, Nevsimalova S, Bassetti C, Bourgin P, Nishino S, Mignot E. Sleep. 2006; 29 (8): 1017-24
• Different periodicity and time structure of leg movements during sleep in narcolepsy/cataplexy and restless legs syndrome. Ferri R, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, Vandi S, Montagna P, Mignot E, Plazzi G. Sleep. 2006; 29 (12): 1587-94
• Narcolepsy-cataplexy associated with precocious puberty. Plazzi G, Parmeggiani A, Mignot E, Lin L, Scano MC, Posar A, Bernardi F, Lodi R, Tonon C, Barbiroli B, Montagna P, Cicognani A. Neurology. 2006; 66 (10): 1577-9
• Regulation of hypocretin (orexin) expression in embryonic zebrafish. Faraco JH, Appelbaum L, Marin W, Gaus SE, Mourrain P, Mignot E. J Biol Chem. 2006; 281 (40): 29753-61
• The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Zeitzer JM, Nishino S, Mignot E. Trends Pharmacol Sci. 2006; 27 (7): 368-74
• A link between short sleep and obesity: building the evidence for causation. Cizza G, Skarulis M, Mignot E. Sleep. 2005; 28 (10): 1217-20
• CSF hypocretin levels are normal in Huntington's disease patients. Gaus SE, Lin L, Mignot E. Sleep. 2005; 28 (12): 1607-8
• Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Crocker A, España RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T, Honda M, Mignot E, Scammell TE. Neurology. 2005; 65 (8): 1184-8
• Emerging therapies in narcolepsy-cataplexy. Mignot E, Nishino S. Sleep. 2005; 28 (6): 754-63
• History of the development of sleep medicine in the United States. Shepard JW, Buysse DJ, Chesson AL, Dement WC, Goldberg R, Guilleminault C, Harris CD, Iber C, Mignot E, Mitler MM, Moore KE, Phillips BA, Quan SF, Rosenberg RS, Roth T, Schmidt HS, Silber MH, Walsh JK, White DP. J Clin Sleep Med. 2005; 1 (1): 61-82
• Hypocretin deficiency in Prader-Willi syndrome. Nevsimalova S, Vankova J, Stepanova I, Seemanova E, Mignot E, Nishino S. Eur J Neurol. 2005; 12 (1): 70-2
• Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, Mignot E, Bassetti CL. Neurology. 2005; 65 (1): 147-9
• Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. Brain. 2005; 128 (Pt 12): 2763-76
• Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Chen W, Black J, Call P, Mignot E. Ann Neurol. 2005; 58 (3): 489-90
• Polymorphisms within the canine MLPH gene are associated with dilute coat color in dogs. Philipp U, Hamann H, Mecklenburg L, Nishino S, Mignot E, Günzel-Apel AR, Schmutz SM, Leeb T. BMC Genet. 2005: 6 34
• The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J, deLahunta A, Lin L, Mignot E. J Vet Intern Med. 2004 Jul-Aug; 18 (4): 586-8
• APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline S, Givelber RJ, Young T. Neurology. 2004; 63 (4): 664-8
• Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension. Lin L, Finn L, Zhang J, Young T, Mignot E. Am J Respir Crit Care Med. 2004; 170 (12): 1349-53
• Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, Lammers GJ. Neurology. 2004; 62 (1): 138-40
• Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation. Pedrazzoli M, D'Almeida V, Martins PJ, Machado RB, Ling L, Nishino S, Tufik S, Mignot E. Brain Res. 2004; 995 (1): 1-6
• Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Zhang S, Zeitzer JM, Yoshida Y, Wisor JP, Nishino S, Edgar DM, Mignot E. Sleep. 2004; 27 (4): 619-27
• Locomotor-dependent and -independent components to hypocretin-1 (orexin A) regulation in sleep-wake consolidating monkeys. Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E. J Physiol. 2004; 557 (Pt 3): 1045-53
• Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. Am J Hum Genet. 2004; 74 (1): 160-7
• Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Eur Neurol. 2004; 52 (2): 73-6
• Sleep, sleep disorders and hypocretin (orexin). Mignot E, Sleep Med. 2004: 5 Suppl 1 S2-8
• Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy. Arnulf I, Mignot E. Sleep. 2004; 27 (7): 1242-3
• The diurnal rhythm of hypocretin in young and old F344 rats. Desarnaud F, Murillo-Rodriguez E, Lin L, Xu M, Gerashchenko D, Shiromani SN, Nishino S, Mignot E, Shiromani PJ. Sleep. 2004; 27 (5): 851-6
• The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Okura M, Fujiki N, Kita I, Honda K, Yoshida Y, Mignot E, Nishino S. Neurobiol Dis. 2004; 16 (1): 274-82
• Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma. Castillo PR, Mignot E, Woodruff BK, Boeve BF. Neurology. 2004; 62 (10): 1909
• CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, Watanabe M, Lammers GJ, Ishiguro H, Shoji S, Nishida Y, Overeem S, Toyoshima I, Yoshida Y, Shimizu T, Taheri S, Mignot E. Neurology. 2003; 61 (6): 823-5
• CSF hypocretin-1 levels in restless legs syndrome. Stiasny-Kolster K, Mignot E, Ling L, Möller JC, Cassel W, Oertel WH. Neurology. 2003; 61 (10): 1426-9
• Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. J Neurosci. 2003; 23 (8): 3555-60
• Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E. Biol Psychiatry. 2003; 54 (2): 96-104
• Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Sleep. 2003; 26 (8): 953-9
• Normal hypocretin-1 levels in the cerebrospinal fluid of patients with fatal familial insomnia. Martínez-Rodríguez JE, Sanchez-Valle R, Saiz A, Lin L, Iranzo A, Mignot E, Santamaria J. Sleep. 2003; 26 (8): 1068
• On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Mignot E, Chen W, Black J. Sleep. 2003; 26 (6): 646-9
• Relationship between CSF hypocretin levels and hypocretin neuronal loss. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, Mignot E, Shiromani PJ. Exp Neurol. 2003; 184 (2): 1010-6
• Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Hecht M, Lin L, Kushida CA, Umetsu DT, Taheri S, Einen M, Mignot E. Sleep. 2003; 26 (7): 809-10
• Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Vankova J, Stepanova I, Jech R, Elleder M, Ling L, Mignot E, Nishino S, Nevsimalova S. Sleep. 2003; 26 (4): 427-30
• Voxel-based morphometry in hypocretin-deficient narcolepsy. Overeem S, Steens SC, Good CD, Ferrari MD, Mignot E, Frackowiak RS, van Buchem MA, Lammers GJ. Sleep. 2003; 26 (1): 44-6
• CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP. Psychiatry Res. 2002; 110 (1): 1-7
• Clinical aspects of narcolepsy-cataplexy across ethnic groups. Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Sleep. 2002; 25 (1): 27-35
• Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate. Shiba T, Ozu M, Yoshida Y, Mignot E, Nishino S. Biochem Biophys Res Commun. 2002; 294 (3): 615-20
• Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Mignot E, Taheri S, Nishino S. Nat Neurosci. 2002: 5 Suppl 1071-5
• The role of hypocretins (orexins) in sleep regulation and narcolepsy. Taheri S, Zeitzer JM, Mignot E. Annu Rev Neurosci. 2002: 25 283-313
• A commentary on the neurobiology of the hypocretin/orexin system. Mignot E, Neuropsychopharmacology. 2001; 25 (5 Suppl): S5-13
• A hundred years of narcolepsy research. Mignot E, Arch Ital Biol. 2001; 139 (3): 207-20
• Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. Kadotani H, Kadotani T, Young T, Peppard PE, Finn L, Colrain IM, Murphy GM, Mignot E. JAMA. 2001; 285 (22): 2888-90
• CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, Di Monte D, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FW, Hungs M, Mignot E, Nishino S. Neurology. 2001; 57 (12): 2253-8
• Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Neuroreport. 2001; 12 (5): 993-7
• Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Nishino S, Fujiki N, Ripley B, Sakurai E, Kato M, Watanabe T, Mignot E, Yanai K. Neurosci Lett. 2001; 313 (3): 125-8
• Dopaminergic role in stimulant-induced wakefulness. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. J Neurosci. 2001; 21 (5): 1787-94
• Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, Mignot E, Nishino S. Eur J Neurosci. 2001; 14 (7): 1075-81
• Hypocretin levels in sporadic and familial cases of canine narcolepsy. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Neurobiol Dis. 2001; 8 (3): 525-34
• Hypocretin/orexin, sleep and narcolepsy. Hungs M, Mignot E. Bioessays. 2001; 23 (5): 397-408
• Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Genome Res. 2001; 11 (4): 531-9
• Narcolepsy and the HLA region. Lin L, Hungs M, Mignot E. J Neuroimmunol. 2001; 117 (1-2): 9-20
• Narcoleptic canines display periodic leg movements during sleep. Okura M, Fujiki N, Ripley B, Takahashi S, Amitai N, Mignot E, Nishino S. Psychiatry Clin Neurosci. 2001; 55 (3): 243-4
• Physical and radiation hybrid mapping of canine chromosome 12, in a region corresponding to human chromosome 6p12-q12. Li R, Faraco JH, Lin L, Lin X, Hinton L, Rogers W, Lowe JK, Ostrander EA, Mignot E. Genomics. 2001; 73 (3): 299-315
• Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Hungs M, Lin L, Okun M, Mignot E. Neurology. 2001; 57 (10): 1893-5
• A polymorphism in the human timeless gene is not associated with diurnal preferences in normal adults. Pedrazzoli M, Ling L, Finn L, Kubin L, Young T, Katzenberg D, Mignot E. Sleep Res Online. 2000; 3 (2): 73-6
• Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Riehl J, Honda K, Kwan M, Hong J, Mignot E, Nishino S. Neuropsychopharmacology. 2000; 23 (1): 34-45
• Hypocretin (orexin) deficiency in human narcolepsy. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Lancet. 2000; 355 (9197): 39-40
• Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S. Neuroscience. 2000; 99 (4): 651-9
• Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Neurosci Res. 2000; 38 (4): 437-46
• Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE. Nishino S, Okura M, Mignot E. Sleep Med Rev. 2000; 4 (1): 57-99
• Perspectives in narcolepsy and hypocretin (orexin) research. Mignot E, Sleep Med. 2000; 1 (2): 87-90
• Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Okura M, Riehl J, Mignot E, Nishino S. Neuropsychopharmacology. 2000; 23 (5): 528-38
• Genetic studies in narcolepsy, a disorder affecting REM sleep. Faraco J, Lin X, Li R, Hinton L, Lin L, Mignot E. J Hered. 1999 Jan-Feb; 90 (1): 129-32
• A human period gene (HPER1) polymorphism is not associated with diurnal preference in normal adults. Katzenberg D, Young T, Lin L, Finn L, Mignot E. Psychiatr Genet. 1999; 9 (2): 107-9
• Construction and characterization of an eightfold redundant dog genomic bacterial artificial chromosome library. Li R, Mignot E, Faraco J, Kadotani H, Cantanese J, Zhao B, Lin X, Hinton L, Ostrander EA, Patterson DF, de Jong PJ. Genomics. 1999; 58 (1): 9-17
• Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected]. Honda K, Riehl J, Mignot E, Nishino S. Neuroreport. 1999; 10 (14): 3111-8
• Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Honda K, Riehl J, Mignot E, Nishino S. Neuroreport. 1999; 10 (17): 3717-24
• Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Mignot E, Young T, Lin L, Finn L. Sleep. 1999; 22 (3): 347-52
• A CLOCK polymorphism associated with human diurnal preference. Katzenberg D, Young T, Finn L, Lin L, King DP, Takahashi JS, Mignot E. Sleep. 1998; 21 (6): 569-76
• Breeding history of the Stanford colony of narcoleptic dogs. Cederberg R, Nishino S, Dement WC, Mignot E. Vet Rec. 1998; 142 (2): 31-6
• Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Nishino S, Mignot E, Benson KL, Zarcone VP. Psychiatry Res. 1998; 78 (3): 141-50
• Development of cataplexy in genetically narcoleptic Dobermans. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Exp Neurol. 1998; 152 (2): 292-302
• Genetic and familial aspects of narcolepsy. Mignot E, Neurology. 1998; 50 (2 Suppl 1): S16-22
• Microsatellite single nucleotide polymorphisms in the HLA-DQ region. Lin L, Jin L, Lin X, Voros A, Underhill P, Mignot E. Tissue Antigens. 1998; 52 (1): 9-18
• Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans. Nishino S, Honda K, Riehl J, Okura M, Mignot E. Neuroreport. 1998; 9 (16): 3653-61
• Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Reid MS, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E. Exp Neurol. 1998; 151 (1): 89-104
• DQ microsatellite association studies in three ethnic groups. Lin L, Jin L, Kimura A, Carrington M, Mignot E. Tissue Antigens. 1997; 50 (5): 507-20
• Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. J Neurosci. 1997; 17 (16): 6401-8
• Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G, Rattazzi C, Lin L, Guilleminault C, Grumet FC, Mayer G, Dement WC, Underhill P. Tissue Antigens. 1997; 49 (4): 329-41
• Genetics of narcolepsy and other sleep disorders. Mignot E, Am J Hum Genet. 1997; 60 (6): 1289-302
• HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. Sleep. 1997; 20 (11): 1012-20
• Mesopontine organization of cholinergic and catecholaminergic cell groups in the normal and narcoleptic dog. Tafti M, Nishino S, Liao W, Dement WC, Mignot E. J Comp Neurol. 1997; 379 (2): 185-97
• Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model. Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E. J Neurosci. 1996; 16 (15): 4588-95
• Mutation rate varies among alleles at a microsatellite locus: phylogenetic evidence. Jin L, Macaubas C, Hallmayer J, Kimura A, Mignot E. Proc Natl Acad Sci U S A. 1996; 93 (26): 15285-8
• Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E. Neuroreport. 1996; 7 (12): 1881-6
• Thalidomide, immune modulation and narcolepsy. Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E. Sleep. 1996; 19 (2): 116
• A new DRB1*1202 allele (DRB1*12022) found in association with DQA1*0102 and DQB1*0602 in two black narcoleptic subjects. Behar E, Lin X, Grumet FC, Mignot E. Immunogenetics. 1995; 41 (1): 52
• Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Sleep. 1995; 18 (10): 817-26
• DQCAR microsatellite polymorphisms in three selected HLA class II-associated diseases. Mignot E, Kimura A, Abbal M, Thorsby E, Lin X, Voros A, Macaubas C, Bouissou F, Sollid LM, Cambon-Thomsen A. Tissue Antigens. 1995; 46 (4): 299-304
• Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. Nishino S, Shelton J, Renaud A, Dement WC, Mignot E. J Pharmacol Exp Ther. 1995; 272 (3): 1170-5
• Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC, Mignot E. J Neurosci. 1995; 15 (7 Pt 1): 4806-14
• Narcolepsy and immunity. Mignot E, Tafti M, Dement WC, Grumet FC. Adv Neuroimmunol. 1995; 5 (1): 23-37
• An immunoglobulin switchlike sequence is linked with canine narcolepsy. Mignot E, Bell RA, Rattazzi C, Lovett M, Grumet FC, Dement WC. Sleep. 1994; 17 (8 Suppl): S68-76
• Cholinergic mechanisms in canine narcolepsy--I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Reid MS, Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC, Mignot E. Neuroscience. 1994; 59 (3): 511-22
• Cholinergic mechanisms in canine narcolepsy--II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. Reid MS, Siegel JM, Dement WC, Mignot E. Neuroscience. 1994; 59 (3): 523-30
• Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Reid MS, Tafti M, Nishino S, Siegel JM, Dement WC, Mignot E. Sleep. 1994; 17 (5): 424-35
• Controversies in the diagnosis of narcolepsy. Guilleminault C, Mignot E, Partinen M. Sleep. 1994; 17 (8 Suppl): S1-6
• DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, Underhill P, Guilleminault C, Dement WC, Grumet FC. Sleep. 1994; 17 (8 Suppl): S60-7
• Modafinil binds to the dopamine uptake carrier site with low affinity. Mignot E, Nishino S, Guilleminault C, Dement WC. Sleep. 1994; 17 (5): 436-7
• Neuropharmacology and neurochemistry of canine narcolepsy. Nishino S, Reid MS, Dement WC, Mignot E. Sleep. 1994; 17 (8 Suppl): S84-92
• Stability of cataplexy over several months--information for the design of therapeutic trials. Gelb M, Guilleminault C, Kraemer H, Lin S, Moon S, Dement WC, Mignot E. Sleep. 1994; 17 (3): 265-73
• Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Sleep. 1993; 16 (8): 706-12
• Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E. J Pharmacol Exp Ther. 1993; 264 (3): 1079-84
• DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. Mignot E, Lin X, Kalil J, George C, Singh S, Billiard M, Montplaisir J, Arrigoni J, Guilleminault C, Dement WC. Sleep. 1992; 15 (5): 415-22
• Monoaminergic uptake in synaptosomes prepared from frozen brain tissue samples of normal and narcoleptic canines. Valtier D, Dement WC, Mignot E. Brain Res. 1992; 588 (1): 115-9
• Dopamine D2 mechanisms in canine narcolepsy. Nishino S, Arrigoni J, Valtier D, Miller JD, Guilleminault C, Dement WC, Mignot E. J Neurosci. 1991; 11 (9): 2666-71
• Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Mignot E, Wang C, Rattazzi C, Gaiser C, Lovett M, Guilleminault C, Dement WC, Grumet FC. Proc Natl Acad Sci U S A. 1991; 88 (8): 3475-8
• Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. Nishino S, Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC, Mignot E. J Pharmacol Exp Ther. 1990; 253 (3): 1145-52
• Evidence for multiple [3H]prazosin binding sites in canine brain membranes. Mignot E, Bowersox SS, Maddaluno J, Dement W, Ciaranello R. Brain Res. 1989; 486 (1): 56-66
• Familial patterns of narcolepsy. Guilleminault C, Mignot E, Grumet FC. Lancet. 1989; 2 (8676): 1376-9
• Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Nishino S, Mignot E, Fruhstorfer B, Dement WC, Hayaishi O. Proc Natl Acad Sci U S A. 1989; 86 (7): 2483-7
• Role of central alpha-1 adrenoceptors in canine narcolepsy. Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC. J Clin Invest. 1988; 82 (3): 885-94